全球微流体市场：2025-2030年预测

微流体市场预计将从 2025 年的 336.9 亿美元成长到 2030 年的 476.9 亿美元，复合年增长率为 7.20%。

预计微流体市场将在2025年至2030年间强劲增长，这得益于照护现场（POC）需求的不断增长、实验室晶片技术的进步以及医疗保健领域对高性能筛检日益增长的需求。微流体能够精确操作微小样本，对于开发用于癌症检测和传染病检查等应用的可携式高效诊断设备至关重要。技术创新和不断上涨的医疗成本（尤其是在美国）推动市场的发展。挑战包括高昂的开发成本和监管障碍。

市场驱动因素

对照护现场(POC) 设备的需求不断增长

即时诊断（POC）的日益普及，尤其是在医疗保健领域，是微流体市场的主要驱动力。这些设备利用微流体技术，能够快速、可携式检测新冠病毒（SARS-CoV-2）、血糖浓度和心臟标记等疾病，从而提高可及性和效率。例如，尿液试纸和肌钙蛋白检测等POC检测的广泛应用依赖于微流体平台进行精确的小体积样本分析。由于微流体支援小型化和经济实惠，诊所和家庭对分散式检查的需求正在推动市场发展。

诊断技术的进步

微流体（例如实验室晶片系统）的创新，透过实现快速精准的诊断，正在推动市场成长。 2023年7月，赛默飞世尔科技推出了Diomni企业软体，以简化分子检测并提高实验室效率。这些进步提高了诊断的准确性和适应性，支持癌症检测等应用，而微流体在这些应用中可以实现早期分析和个人化治疗。美国癌症发生率的上升凸显了对此类技术的需求，进一步推动了市场扩张。

医疗支出增加

医疗保健支出的不断增长，尤其是在美国，正在推动微流体在高阶诊断领域的应用。美国医疗保健产业正在大力投资创新解决方案，从而增加了对基于微流体技术的即时检测 (POC) 设备的需求，这些设备可以改善患者治疗效果并降低成本。对慢性病精准诊断的关注以及微流体在高性能筛检中的整合是推动该地区市场成长的关键因素。

市场限制

微流体市场面临挑战，因为高昂的开发和製造成本可能会限制其在成本敏感地区和应用领域的应用。复杂的监管环境，包括严格的医疗设备审批标准，构成了市场准入的障碍。此外，设计和操作微流体系统所需的专业知识可能会阻碍其在新兴市场的成长。透过经济高效的生产和精简的监管流程来应对这些挑战，对于持续扩张至关重要。

目录

第一章执行摘要

第二章市场概述

• 市场概览
• 市场定义
• 调查范围
• 市场区隔

第三章 经营状况

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策法规
• 策略建议

第四章 技术展望

5. 全球微流体市场（按组件）

• 介绍
• 尖端
• 泵浦
• 感应器
• 其他的

6. 全球微流体市场区隔

• 介绍
• 产业
• 卫生保健

7. 全球微流体市场（按应用）

• 介绍
• 照护现场诊断（POC）
• 药物输送系统
• 体外诊断（IVD）
• 製药与生命科学研究

第八章微流体市场（按地区）

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章竞争格局及分析

• 主要企业和策略分析
• 市场占有率分析
• 合併、收购、协议和合作
• 竞争对手仪表板

第十章：公司简介

• Illumina, Inc.
• F. Hoffman-La Roche Ltd
• PerkinElmer, Inc
• Agilent Technologies, Inc
• Bio-Rad Laboratories, Inc
• Abbott
• Standard BioTools
• Agilent Technologies
• Thermo Fisher Scientific
• Danaher Corporation

第十一章 附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要利益
• 调查方法
• 简称

The Global Microfluidics Market is expected to grow from USD 33.690 billion in 2025 to USD 47.696 billion in 2030, at a CAGR of 7.20%.

The global microfluidics market is projected to experience robust growth from 2025 to 2030, driven by the increasing demand for point-of-care (POC) diagnostics, advancements in lab-on-a-chip technologies, and the rising need for high-throughput screening in healthcare. Microfluidics, enabling precise manipulation of low-volume samples, is critical for developing portable, efficient diagnostic devices used in applications like cancer detection and infectious disease testing. The market is propelled by technological innovations and growing healthcare expenditures, particularly in the United States. Challenges include high development costs and regulatory hurdles.

Market Drivers

Rising Demand for Point-of-Care (POC) Devices

The increasing adoption of POC diagnostics, particularly in healthcare, is a primary driver of the microfluidics market. These devices, leveraging microfluidic technology, enable rapid, portable testing for conditions like SARS-CoV-2, glucose levels, and cardiac markers, enhancing accessibility and efficiency. For instance, widespread use of POC tests, such as urine dipstick and troponin assays, relies on microfluidic platforms for accurate, low-volume sample analysis. The demand for decentralized testing in clinics and home settings is boosting the market, as microfluidics supports miniaturization and affordability.

Advancements in Diagnostic Technologies

Innovations in microfluidics, such as lab-on-a-chip systems, are driving market growth by enabling rapid and precise diagnostics. In July 2023, Thermo Fisher Scientific launched Diomni Enterprise Software, streamlining molecular testing and enhancing lab efficiency. Such advancements improve diagnostic accuracy and adaptability, supporting applications like cancer detection, where microfluidics enables early-stage analysis and personalized treatment. The rising incidence of cancer in the United States underscores the need for these technologies, further fueling market expansion.

Growing Healthcare Expenditure

Increasing healthcare spending, particularly in the United States, is supporting the adoption of microfluidics in advanced diagnostics. The U.S. healthcare industry's substantial investment in innovative solutions drives demand for microfluidic-based POC devices that improve patient outcomes and reduce costs. The focus on precision diagnostics for chronic diseases and the integration of microfluidics in high-throughput screening are key factors enhancing market growth in this region.

Market Restraints

The microfluidics market faces challenges due to high development and manufacturing costs, which can limit adoption in cost-sensitive regions or applications. Regulatory complexities, including stringent standards for medical device approval, pose barriers to market entry. Additionally, the need for specialized expertise to design and operate microfluidic systems may hinder growth in emerging markets. Addressing these challenges through cost-effective production and streamlined regulatory processes will be critical for sustained expansion.

Market Segmentation

By Application

The market is segmented into POC diagnostics, in vitro diagnostics (IVD), high-throughput screening, and others. POC diagnostics dominate due to their widespread use in healthcare for rapid testing. IVD and high-throughput screening are growing segments, driven by demand for precision diagnostics and drug development.

By Technology

The market includes lab-on-a-chip, microfluidic cartridges, and others. Lab-on-a-chip leads due to its versatility in diagnostics, while microfluidic cartridges are critical for POC applications.

By Geography

The market is segmented into North America, Asia-Pacific, Europe, South America, and the Middle East and Africa. North America, led by the United States, holds a significant share due to its large healthcare market and focus on advanced diagnostics. Asia-Pacific is expected to grow rapidly, driven by increasing healthcare investments and industrialization in countries like China and India. Europe, South America, and the Middle East and Africa are emerging markets with growing potential.

The microfluidics market is set for robust growth from 2025 to 2030, driven by demand for POC diagnostics, advancements in lab-on-a-chip technologies, and rising healthcare expenditures. Innovations like Thermo Fisher's Diomni Enterprise Software, launched in July 2023, highlight the market's transformative potential. Despite challenges like high costs and regulatory hurdles, the outlook is positive, particularly in North America and Asia-Pacific. Industry players must focus on cost-effective, scalable solutions to capitalize on the growing demand for microfluidics in precision diagnostics and healthcare applications.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2020 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

By Component

• Chips
• Pumps
• Sensors
• Others

By Sector

• Industrial
• Healthcare

By Application

• Point-of-care (POC) Diagnostics
• Drug Delivery Systems
• In-Vitro Diagnostics (IVD)
• Pharmaceutical and Life Sciences Research

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL MICROFLUIDS MARKET BY COMPONENT

• 5.1. Introduction
• 5.2. Chips
• 5.3. Pumps
• 5.4. Sensors
• 5.5. Others

6. GLOBAL MICROFLUIDS MARKET BY SECTOR

• 6.1. Introduction
• 6.2. Industrial
• 6.3. Healthcare

7. GLOBAL MICROFLUIDS MARKET BY APPLICATION

• 7.1. Introduction
• 7.2. Point-of-care (POC) Diagnostics
• 7.3. Drug Delivery Systems
• 7.4. In-Vitro Diagnostics (IVD)
• 7.5. Pharmaceutical and Life Sciences Research

8. GLOBAL MICROFLUIDS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Illumina, Inc.
• 10.2. F. Hoffman-La Roche Ltd
• 10.3. PerkinElmer, Inc
• 10.4. Agilent Technologies, Inc
• 10.5. Bio-Rad Laboratories, Inc
• 10.6. Abbott
• 10.7. Standard BioTools
• 10.8. Agilent Technologies
• 10.9. Thermo Fisher Scientific
• 10.10. Danaher Corporation

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations